Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

抗凝药物治疗静脉血栓栓塞症争议与共识

2021-12-01 首都医科大学附属北京世纪坛医院血管外科 中国实用外科杂志

静脉血栓栓塞抗凝药物静脉系统疾病

静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺动脉栓塞(PE),是同一疾病在不同阶段和身体不同部位的两种表现形式。VTE是仅次于心脏病和中风后的第三大常见心血管疾病死亡原因。美国每年>

中文标题：

抗凝药物治疗静脉血栓栓塞症争议与共识

发布机构：

首都医科大学附属北京世纪坛医院血管外科

发布日期：

2021-12-01

简要介绍：

静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺动脉栓塞(PE),是同一疾病在不同阶段和身体不同部位的两种表现形式。VTE是仅次于心脏病和中风后的第三大常见心血管疾病死亡原因。美国每年>900 000例病人发生症状性VTE,除带来巨大的医疗负担外,其中300 000例病人死于PE。1949年,抗凝被作为首选治疗方法引入我国后,至今仍占据VTE一线治疗地位。然而,虽然到目前为止我国已经在VTE的诊治中积累了丰富经验,但依然存在一些问题尚待研究和解决。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=抗凝药物治疗静脉血栓栓塞症争议与共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cb73f1c002328e6f, title=抗凝药物治疗静脉血栓栓塞症争议与共识, enTitle=, guiderFrom=中国实用外科杂志, authorId=0, author=, summary=静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺动脉栓塞(PE),是同一疾病在不同阶段和身体不同部位的两种表现形式。VTE是仅次于心脏病和中风后的第三大常见心血管疾病死亡原因。美国每年>, cover=https://img.medsci.cn/2022119/1642574234555_5579292.jpg, journalId=0, articlesId=null, associationId=2322, associationName=首都医科大学附属北京世纪坛医院血管外科, associationIntro=首都医科大学附属北京世纪坛医院血管外科, copyright=0, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺动脉栓塞(PE),是同一疾病在不同阶段和身体不同部位的两种表现形式。VTE是仅次于心脏病和中风后的第三大常见心血管疾病死亡原因。美国每年&gt;900 000例病人发生症状性VTE,除带来巨大的医疗负担外,其中300 000例病人死于PE。1949年,抗凝被作为首选治疗方法引入我国后,至今仍占据VTE一线治疗地位。然而,虽然到目前为止我国已经在VTE的诊治中积累了丰富经验,但依然存在一些问题尚待研究和解决。&nbsp;</span></p>, tagList=[TagDto(tagId=3164, tagName=静脉血栓栓塞), TagDto(tagId=8827, tagName=抗凝药物), TagDto(tagId=117835, tagName=静脉系统疾病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9401, appHits=772, showAppHits=0, pcHits=886, showPcHits=8621, likes=2, shares=120, comments=27, approvalStatus=1, publishedTime=Wed Jan 19 14:35:44 CST 2022, publishedTimeString=2021-12-01, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Jan 19 14:40:30 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 11:08:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=抗凝药物治疗静脉血栓栓塞症争议与共识.pdf)])
抗凝药物治疗静脉血栓栓塞症争议与共识.pdf
下载请点击：
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2116868, encodeId=e4ff211686858, content=我想下载没积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=becf8562044, createdName=ms5000000227127449, createdTime=Tue Feb 28 11:11:44 CST 2023, time=2023-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=55239, encryptionId=546555239e8, topicName=抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:07:49 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238298, encodeId=f6dc1238298a2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Fri Aug 12 15:56:22 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230170, encodeId=c01412301e07e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/vJ58nhiaP6EY9qnGhDmrpQ8huOnnHCWI9aP6Y5MiaOVsvnmqsQpFNAPic914llgrAtvsBWdg3o189sDM1Z4HxShgQ/132, createdBy=74e82537825, createdName=1342515b7am, createdTime=Sat Jul 02 19:44:24 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227228, encodeId=7276122e228a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eouShoVRPZvFshog2V4Bs8JhDIybaiaNUp16CYicwfDeRB6KoOUPj3fibYhRSsWDJ2LGJM8fFQVIrdnQ/132, createdBy=f44f2325690, createdName=苏新攀, createdTime=Sat Jun 18 17:11:09 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2023-02-28 ms5000000227127449 来自江苏省

    我想下载没积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2116868, encodeId=e4ff211686858, content=我想下载没积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=becf8562044, createdName=ms5000000227127449, createdTime=Tue Feb 28 11:11:44 CST 2023, time=2023-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=55239, encryptionId=546555239e8, topicName=抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:07:49 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238298, encodeId=f6dc1238298a2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Fri Aug 12 15:56:22 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230170, encodeId=c01412301e07e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/vJ58nhiaP6EY9qnGhDmrpQ8huOnnHCWI9aP6Y5MiaOVsvnmqsQpFNAPic914llgrAtvsBWdg3o189sDM1Z4HxShgQ/132, createdBy=74e82537825, createdName=1342515b7am, createdTime=Sat Jul 02 19:44:24 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227228, encodeId=7276122e228a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eouShoVRPZvFshog2V4Bs8JhDIybaiaNUp16CYicwfDeRB6KoOUPj3fibYhRSsWDJ2LGJM8fFQVIrdnQ/132, createdBy=f44f2325690, createdName=苏新攀, createdTime=Sat Jun 18 17:11:09 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-08-28 循证小兵

    #静脉血栓栓塞#与#抗凝药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2116868, encodeId=e4ff211686858, content=我想下载没积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=becf8562044, createdName=ms5000000227127449, createdTime=Tue Feb 28 11:11:44 CST 2023, time=2023-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=55239, encryptionId=546555239e8, topicName=抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:07:49 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238298, encodeId=f6dc1238298a2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Fri Aug 12 15:56:22 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230170, encodeId=c01412301e07e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/vJ58nhiaP6EY9qnGhDmrpQ8huOnnHCWI9aP6Y5MiaOVsvnmqsQpFNAPic914llgrAtvsBWdg3o189sDM1Z4HxShgQ/132, createdBy=74e82537825, createdName=1342515b7am, createdTime=Sat Jul 02 19:44:24 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227228, encodeId=7276122e228a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eouShoVRPZvFshog2V4Bs8JhDIybaiaNUp16CYicwfDeRB6KoOUPj3fibYhRSsWDJ2LGJM8fFQVIrdnQ/132, createdBy=f44f2325690, createdName=苏新攀, createdTime=Sat Jun 18 17:11:09 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-08-12 1472d9b8m50暂无昵称

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2116868, encodeId=e4ff211686858, content=我想下载没积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=becf8562044, createdName=ms5000000227127449, createdTime=Tue Feb 28 11:11:44 CST 2023, time=2023-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=55239, encryptionId=546555239e8, topicName=抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:07:49 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238298, encodeId=f6dc1238298a2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Fri Aug 12 15:56:22 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230170, encodeId=c01412301e07e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/vJ58nhiaP6EY9qnGhDmrpQ8huOnnHCWI9aP6Y5MiaOVsvnmqsQpFNAPic914llgrAtvsBWdg3o189sDM1Z4HxShgQ/132, createdBy=74e82537825, createdName=1342515b7am, createdTime=Sat Jul 02 19:44:24 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227228, encodeId=7276122e228a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eouShoVRPZvFshog2V4Bs8JhDIybaiaNUp16CYicwfDeRB6KoOUPj3fibYhRSsWDJ2LGJM8fFQVIrdnQ/132, createdBy=f44f2325690, createdName=苏新攀, createdTime=Sat Jun 18 17:11:09 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-07-02 1342515b7am

    受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2116868, encodeId=e4ff211686858, content=我想下载没积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=becf8562044, createdName=ms5000000227127449, createdTime=Tue Feb 28 11:11:44 CST 2023, time=2023-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241573, encodeId=965712415e3e3, content=<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a>与<a href='/topic/show?id=546555239e8' target=_blank style='color:#2F92EE;'>#抗凝药物#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=55239, encryptionId=546555239e8, topicName=抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:07:49 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238298, encodeId=f6dc1238298a2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Fri Aug 12 15:56:22 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230170, encodeId=c01412301e07e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/vJ58nhiaP6EY9qnGhDmrpQ8huOnnHCWI9aP6Y5MiaOVsvnmqsQpFNAPic914llgrAtvsBWdg3o189sDM1Z4HxShgQ/132, createdBy=74e82537825, createdName=1342515b7am, createdTime=Sat Jul 02 19:44:24 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227228, encodeId=7276122e228a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eouShoVRPZvFshog2V4Bs8JhDIybaiaNUp16CYicwfDeRB6KoOUPj3fibYhRSsWDJ2LGJM8fFQVIrdnQ/132, createdBy=f44f2325690, createdName=苏新攀, createdTime=Sat Jun 18 17:11:09 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-06-18 苏新攀

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 ASMBS立场声明：减重手术围手术期静脉血栓栓塞的预防

美国代谢和减肥外科学会(ASMBS,American Society for Metabolic &amp; Bariatric Surgery) · 2021-11-10

2021 NICE指南：成人静脉血栓栓塞

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-08-19

2020 SIR临床实践指南：下腔静脉滤器在静脉血栓栓塞症患者治疗中的应用

介入放射学会(SIR,Society of Interventional Radiology) · 2020-09-02

2016 ISTH指南：已引起或未引起静脉血栓栓塞的病人的分类

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2016-04-15

2017 ISTH指南：静脉血栓栓塞患者的隐匿性癌症筛查

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2017-08-09

2018 ISTH指南：儿童癌症危险患者的识别及静脉血栓栓塞症的预防

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2017-11-27

Baidu
map
Baidu
map
Baidu
map